Huntington's Disease Studies

Huntington's disease (HD) is an autosomal neurodegenerative disorder characterized by motor, behavioral, cognitive and metabolic dysfunction caused by the expansion of a CAG trinucleotide repeat region in the huntingtin gene (HTT).

Charles River has a long-standing track record for providing HD lead compound efficacy screening services. Fully customized studies with two internally validated mouse models, the transgenic R6/2 mouse and the Q175 knock-in mouse, capture all aspects of efficacy screening.

The models are accompanied by behavior and cognitive testing, magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). In addition, several relevant biomarkers, such as immunohistochemical measurements and qPCR, can be included to further expand the platform.

You may also be interested in...

Biomarker Services

We can support your drug discovery pipeline by providing biomarker analysis in a non-GxP environment.

Imaging Services

Imaging Services

Our range of imaging modalities can dramatically increase the efficiency and significantly enhance the value of your study.